Partner Headlines - POZN

  1. Markets Little Changed Ahead Of The Federal Reserve's Policy ...

    Benzinga
  2. Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! ...

    Benzinga
  3. Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher

    Benzinga
  4. Morning Market Losers

    Benzinga
  5. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
  6. POZEN Receives CRL From FDA

    Benzinga
  7. Morning Market Losers

    Benzinga
  8. Benzinga's Top #PreMarket Losers

    Benzinga
  9. Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study ...

    Benzinga
  10. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga
  11. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  12. Morning Market Losers

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Benzinga's Top Downgrades

    Benzinga
  15. POZEN New PA8140/PA32540 PDUFA Date is April 25, 2014

    Benzinga
  16. POZEN Announces December 31, 2013 as Ex-Dividend Date for Previously ...

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. POZEN Announces Special Cash Distribution of $1.75/Share

    Benzinga
  19. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga
  20. Benzinga's Top Pre-Market Gainers

    Benzinga
  21. Stocks To Watch For September 5, 2013

    Benzinga
  22. SANOFI

    IBD
  23. Sanofi, Pozen Announce Exclusive License Deal for Commercialization ...

    Benzinga
  24. Pozen Inc. Reports Operating Results (10-Q)

    GuruFocus
  25. UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future ...

    Benzinga
  26. POZEN Announces PA32540 Provides Superior Antiplatlet Effects ...

    Benzinga
  27. POZEN Provides Positive Update on Its PA Program and Results ...

    Benzinga
  28. POZEN Receives Patent on PA Products for Treatment of Cardiovascular ...

    Benzinga
  29. Celgene, Bed Bath & Beyond Among Stocks Gapping Down Thursday

    FoxBusiness
  30. Morning Market Losers

    Benzinga
  31. POZEN Says FDA Does Not Agree That BioEquivalence Was Demonstrated

    Benzinga
  32. POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH ...

    Benzinga
Trading Center